# Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

> **NCT01092065** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 23 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** AFQ056 with L-dopa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01092065
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2020-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01092065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01092065, "Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01092065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*